Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 14/20 | 0.48 |
| ▸ | PGR | P06401 | 6/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4248651 | 0.91 | CCR5 (0.44) | CCR5PGRCYP2C9CYP2D6KCNH2 | |
| SCHEMBL4240473 | 0.89 | CCR5 (0.46) | CCR5PGRCYP2C9CYP2D6KCNH2 | |
| SCHEMBL4236391 | 0.89 | CCR5 (0.48) | CCR5PGRCYP2C9CYP2D6 | |
| SCHEMBL4240580 | 0.88 | CCR5 (0.44) | CCR5PGRCYP2C9CYP2D6KCNH2 | |
| SCHEMBL4245286 | 0.87 | CCR5 (0.48) | CCR5PGRCYP2C9CYP2D6 | |
| SCHEMBL4240149 | 0.87 | CCR5 (0.47) | CCR5PGRCYP2C9CYP2D6 | |
| SCHEMBL4239099 | 0.87 | CCR5 (0.60) | CCR5KCNH2 | |
| SCHEMBL4248545 | 0.87 | CCR5 (0.54) | CCR5PGRCYP2C9CYP2D6 | |
| SCHEMBL4249160 | 0.86 | CCR5 (0.51) | CCR5KCNH2 | |
| SCHEMBL4238957 | 0.85 | CCR5 (0.49) | CCR5PGRCYP2C9CYP2D6KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7491735-B2 | Chemokine receptor binding compounds | GENZYME CORPORATION (US) | 2009-02-17 | — | — | US | claimed |
| EP-1708703-A4 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED INC (CA) | 2008-04-09 | — | — | EP | claimed |
| EP-1708703-A2 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED INC. (CA) | 2006-10-11 | — | — | EP | claimed |
| US-20050277670-A1 | Chemokine receptor binding compounds | ANORMED INC. | 2005-12-15 | — | — | US | claimed |
| WO-2005059107-A2 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED INC. (CA) | 2005-06-30 | — | — | WO | claimed |
| US-7491735-B2 | Chemokine receptor binding compounds | GENZYME CORPORATION (US) | 2009-02-17 | — | — | US | disclosed |
| US-20050277670-A1 | Chemokine receptor binding compounds | ANORMED INC. | 2005-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277670-A1 | Chemokine receptor binding compounds | CCR5, CXCR3, CCL5 | CCR5 1/4885PGR 976/4885CYP2C9 4329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.